Bixiye
QP94-22 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: Nov 09, 2022
Natiijooyinka Raadinta
Soo bandhiga 1631 - 1640 ee natiijooyinka 3688
Bixiye
QP93-22 MHCP Pharmacy Benefit Exclusion for Pedmark®, Rolvedon™, Skysona®, Spevigo®, and Xenpozyme™
Taariikhda uu dhaqangalayo Barnaamijka: Nov 09, 2022
Bixiye
QP90-22 Provider Press: Q4 2022
Taariikhda uu dhaqangalayo Barnaamijka: Nov 09, 2022
Bixiye
QP84-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Camzyos™ (mavacamten)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
QP85-22 MHCP Pharmacy Benefit Update: New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Radicava® (edaravone)
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022
Bixiye
P70-22 Medicare Advantage Behavioral Health Claims Update
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2022
Bixiye
P68-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2022
Sharciga & Xeerar
bcbs-gender-affirming-policy-doc-require-highlighted.pdf
Sharciga & Xeerar
bcbs-gender-affirming-policy-hrt-language-highlighted.pdf
Bixiye
QP88-22 Provider Press: Q2 2022
Taariikhda uu dhaqangalayo barnaamijka: Okt 26, 2022